SAN CLEMENTE, Calif. and ST. LOUIS, June 7, 2012 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI) and Mobius Therapeutics, LLC today jointly announced that ICU Medical's ChemoClave™ system for the safe handling of hazardous drugs will be packaged with Mobius Therapeutics' Mitosol® kit, an FDA-cleared drug used in ophthalmic surgery containing the active ingredient Mitomycin-C, which is cytotoxic and listed on NIOSH Hazardous Drug List. By incorporating ChemoClave components into the kit, clinicians will be able to reconstitute Mitosol on the surgical field, improving shelf life and consistency of the delivered drug, without changing current surgical technique. Both the ChemoClave system and the Mitosol kit can be seen at the upcoming American Society of Health System Pharmacists (ASHP) Summer meeting in Baltimore, MD June 10-12, 2012.
"Although the use of mitomycin in eye surgery has been well established by medical literature, the compound is highly unstable and can present a hazard to doctors and nurses in the operating room when preparing the drug," explained Mobius Therapeutics President Ed Timm. "By incorporating the ChemoClave system into the Mitosol kit, we can minimize potential hazards for clinicians in the operating room and provide patients with a product that is consistent, assuredly sterile, and assuredly potent since it is mixed using the completely closed, sterile ChemoClave system."
Media Contact: Tom McCall
Vice President, Marketing
About ICU Medical, Inc.: ICU Medical, Inc. develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. ICU Medical's products improve patient outcomes by helping prevent bloodstream infections and protecting healthcare workers from exposure to infectious diseases or hazardous drugs. The company's complete product line includes custom I.V. systems, closed delivery systems for hazardous drugs, needle-free I.V. connectors, catheters and cardiac monitoring systems. ICU Medical is headquartered in San Clemente, California. For more information, visit www.icumed.com.
About Mobius Therapeutics, LLC: Mobius Therapeutics is an early stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the refractive and corneal indications are awaiting approval by the Food and Drug Administration.
SOURCE ICU Medical, Inc.